Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522188 | 0.99 | EGLN1 (0.56) | EGLN1EGLN2 | |
| SCHEMBL30274573 | 0.99 | EGLN1 (0.56) | EGLN1EGLN2 | |
| SCHEMBL5070941 | 0.81 | EGLN1 (0.53) | EGLN1EGLN2 | |
| SCHEMBL522924 | 0.80 | EGLN1 (0.77) | EGLN1EGLN2 | |
| SCHEMBL30274444 | 0.80 | EGLN1 (0.77) | EGLN1EGLN2 | |
| SCHEMBL523651 | 0.79 | EGLN1 (0.66) | EGLN1EGLN2 | |
| SCHEMBL522771 | 0.78 | EGLN2 (0.82) | EGLN1EGLN2 | |
| SCHEMBL522832 | 0.78 | EGLN1 (0.64) | EGLN1EGLN2 | |
| SCHEMBL523800 | 0.77 | EGLN1 (0.66) | EGLN1EGLN2 | |
| SCHEMBL1216041 | 0.77 | EGLN1 (0.66) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885EGLN2 8/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885EGLN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.